Glaxo Won't Block Generic Of Zantac Syrup

Law360, New York (January 28, 2008, 12:00 AM EST) -- Cypress Pharmaceutical has reached a settlement agreement with a GlaxoSmithKline unit, putting to rest all disputes between the two companies related to the syrup form of the ulcer drug Zantac, Cypress announced Friday.

Under the deal Glaxo Group Limited, part of the GlaxoSmithKline group of companies, has agreed not to assert its patent against Cypress' new alcohol-free formulation of its generic ranitidine oral syrup, according to Madison, Miss.-based Cypress.

Ranitidine, the active ingredient in Zantac, is used to treat and prevent ulcers, gastroesophageal reflux disorder and...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.